A common constipation drug shows surprising power to protect kidneys
A common constipation drug may have unexpectedly unlocked a new way to slow chronic kidney disease — a condition that affects millions and often leads to dialysis. In a clinical trial involving 150 patients, researchers found that lubiprostone, a medication normally used to treat constipation, helped preserve kidney function in people with moderate CKD. Scientists traced the effect to changes in gut bacteria that boosted production of spermidine, a compound linked to healthier mitochondria and reduced kidney damage.
A common constipation drug may have unexpectedly unlocked a new way to slow chronic kidney disease — a condition that affects millions and often leads to dialysis. In a clinical trial involving 150 patients, researchers found that lubiprostone, a medication normally used to treat constipation, helped preserve kidney function in people with moderate CKD. Scientists…
A common constipation drug may have unexpectedly unlocked a new way to slow chronic kidney disease — a condition that affects millions and often leads to dialysis. In a clinical trial involving 150 patients, researchers found that lubiprostone, a medication normally used to treat constipation, helped preserve kidney function in people with moderate CKD. Scientists traced the effect to changes in gut bacteria that boosted production of spermidine, a compound linked to healthier mitochondria and reduced kidney damage.
The full story continues on Science Daily.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.